🔎 Trials Near Me

Gara Jalqabaatti › Kansaar Onnee Triple-Negative › Virginia › Norfolk

Qorannoo klinikaalii Kansaar Onnee Triple-Negative Norfolk, VA keessatti

Qorannoo 5 Kansaar Onnee Triple-Negative f Norfolk fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.

Takkalaa qorannoo (Ingiliffa)

Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Namoota walitti qabaa jiraSadarkaa 3
  • Virginia Oncology Associates (VOA) ( Site 8002), Norfolk
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06841354

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Namoota walitti qabaa jiraSadarkaa 3
  • Virginia Oncology Associates (VOA) ( Site 8008), Norfolk
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06393374

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Namoota walitti qabaa jiraSadarkaa 3
  • Virginia Oncology Associates (VOA) ( Site 8008), Norfolk
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06966700

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Namoota walitti qabaa jiraSadarkaa 1/2
  • USOR Virginia Oncology Associates, Norfolk
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Hag-2026 · NCT05579366

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

Namoota walitti qabaa jiraSadarkaa 1/2
  • Virginia Oncology Associates, Norfolk
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ama-2026 · NCT06926920

Qorannoo Kansaar Onnee Triple-Negative magaalota biroo keessatti

Qorannoo biroo Norfolk keessatti

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.